Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies (Tables)

v3.25.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2025
Summary of Significant Accounting Policies  
Schedule of significant expense categories

Three Months Ended

    

Six Months Ended

June 30, 

June 30, 

June 30, 

June 30, 

2025

    

2024

    

2025

    

2024

Operating expenses:

Clinical

$

1,630,084

$

2,048

$

3,447,316

$

4,322

Chemical, manufacturing and controls

558,916

25,418

694,038

68,055

Research and preclinical

8,094

122,565

32,228

186,280

Regulatory

5,628

27,286

(16)

Other research and development costs

367,221

186,053

806,073

421,160

Total research and development

2,569,943

336,084

5,006,941

679,801

General and administrative expenses

1,353,172

733,740

3,346,100

1,704,124

Total operating expenses

3,923,115

1,069,824

8,353,041

2,383,925

Loss from operations

(3,923,115)

(1,069,824)

(8,353,041)

(2,383,925)

Loss on debt conversion with related party

(6,134,120)

Interest income (expense), net

111,379

19,991

(35,711)

42,757

Exchange gain (loss), net

 

4,532

 

 

(18,742)

 

Net loss before income taxes

$

(3,807,204)

$

(1,049,833)

$

(14,541,614)

$

(2,341,168)